Pixantrone: A novel anthracycline-like drug for the treatment of non-Hodgkin lymphoma

Expert Opinion on Drug Safety

Volumn 14, Issue 4, 2015, Pages 601-607

  Boyle, Eileen Mary ^a,b   Morschhauser, Franck ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Anthracyclines; Cardiotoxicity; Lymphoma; Pixantrone

Indexed keywords

BENDAMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GEMCITABINE; METHYLPREDNISOLONE; PIXANTRONE; PREDNISOLONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; ISOQUINOLINE DERIVATIVE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CARDIOTOXICITY; DRUG EFFICACY; DRUG SAFETY; FEVER; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOLOGIC DISEASE; HUMAN; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; THROMBOCYTOPENIA; ANIMAL; LYMPHOMA, NON-HODGKIN; PATHOLOGY; TIME; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; CARDIOTOXICITY; HUMANS; ISOQUINOLINES; LYMPHOMA, NON-HODGKIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84924959351     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1010505     Document Type: Article

References (41)

1. Coiffier B, Thieblemont C, Van Den Neste E, et al.Long-Term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe dEtudes des Lymphomes de lAdulte.Blood 2010; 116(12): 2040-5
2. Wilson WH, Dunleavy K, Pittaluga S, et al.Phase II study of dose-Adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and postgerminal center biomarkers.J Clin Oncol 2008; 26(16): 2717-24
3. Ketterer N, Coiffier B, Thieblemont C, et al.Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B).Ann Oncol 2013; 24(4): 1032-7
4. Moser EC, Noordijk EM, van Leeuwen FE, et al.Long-Term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma.Blood 2006; 107(7): 2912-19
5. Singal PK, Iliskovic N.Doxorubicin-induced cardiomyopathy.N Engl J Med 1998; 339(13): 900-5
6. Limat S, Daguindau E, Cahn J-Y, et al.Incidence and risk-factors of CHOP/RCHOP-related cardiotoxicity in patients with aggressive non-Hodgkins lymphoma.J Clin Pharm Ther 2014; 39(2): 168-74
7. Hequet O, Le QH, Moullet I, et al.Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.J Clin Oncol 2004; 22(10): 1864-71
8. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA A clinicopathologic analysis of adriamycin cardiotoxicity.Cancer 1973; 32(2): 302-14
9. Salvatorelli E, Menna P, Paz OG, et al.The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-Treated patients.J Pharmacol Exp Ther 2013; 344(2): 467-78
10. Von Hoff DD, Layard M, Rozencweig M, Muggia FM.Time relationship between last dose of daunorubicin and congestive heart failure.Cancer Treat Rep 1977; 61(7): 1411-13
11. Von Hoff DD, Rozencweig M, Layard M, et al.Daunomycin-induced cardiotoxicity in children and adults A review of 110 cases.Am J Med 1977; 62(2): 200-8
12. Billingham ME, Bristow MR, Glatstein E, et al. Adriamycin Cardiotoxicity: Endomyocardial Biopsy Evidence of Enhancement by Irradiation.Am J Surg Pathol 1977; 1(1): 17-23
13. Praga C, Beretta G, Vigo PL, et al.Adriamycin cardiotoxicity: a survey of 1273 patients.Cancer Treat Rep 1979; 63(5): 827-34
14. Kim YD, Lees DE, Lake CR, et al.Hyperthermia potentiates doxorubicinrelated cardiotoxic effects.JAMA 1979; 241(17): 1816-17
15. Minow RA, Benjamin RS, Lee ET, Gottlieb JA.Adriamycin cardiomyopathy - risk factors.Cancer 1977; 39(4): 1397-402
16. Benjamin RS.Pharmacokinetics of adriamycin (NSC-123127) in patients with sarcomas.Cancer Chemother Rep 1974; 58(2): 271-3
17. Minotti G, Menna P, Salvatorelli E, et al.Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity.Pharmacol Rev 2004; 56(2): 185-229
18. Stewart DJ, Grewaal D, Green RM, et al.Concentrations of doxorubicin and its metabolites in human autopsy heart and other tissues.Anticancer Res 1993; 13(6A): 1945-52
19. Doroshow JH, Davies KJ.Comparative cardiac oxygen radical metabolism by anthracycline antibiotics, mitoxantrone, bisantrene, 4-(9-Acridinylamino)-methanesulfon-m-Anisidide, and neocarzinostatin.Biochem Pharmacol 1983; 32(19): 2935-9
20. Gewirtz DA A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin.Biochem Pharmacol 1999; 57(7): 727-41
21. Minotti G, Salvatorelli E, Menna P.Pharmacological foundations of cardio-oncology.J Pharmacol Exp Ther 2010; 334(1): 2-8
22. Blanco JG, Sun C-L, Landier W, et al.Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes - A report from the Childrens Oncology Group.J Clin Oncol 2012; 30(13): 1415-21
23. Salvatorelli E, Menna P, Gianni L, Minotti G.Defective taxane stimulation of epirubicinol formation in the human heart: insight into the cardiac tolerability of epirubicin-Taxane chemotherapies.J Pharmacol Exp Ther 2007; 320(2): 790-800
24. Sonneveld P, de Ridder M, van der Lelie H, et al.Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkins lymphoma using CHOP versus CNOP chemotherapy.J Clin Oncol 1995; 13(10): 2530-9
25. Faulds D, Balfour JA, Chrisp P, Langtry HD.Mitoxantrone A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.Drugs 1991; 41(3): 400-49
26. Longo M, Della Torre P, Allievi C, et al.Tolerability and toxicological profile of pixantrone (Pixuvri) in juvenile mice.Comparative study with doxorubicin.Reprod Toxicol 2014; 46: 20-30
27. Cavalletti E, Crippa L, Mainardi P, et al.Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone.Invest New Drugs 2007; 25(3): 187-95
28. Péan E, Flores B, Hudson I, et al.The European Medicines Agency review of pixantrone for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkins B-cell lymphomas: summary of the scientific assessment of the committee for medicinal products for human use.Oncologist 2013; 18(5): 625-33
29. Pettengell R, Coiffier B, Narayanan G, et al.Pixantrone dimaleate versus other chemotherapeutic agents as a single-Agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial.Lancet Oncol 2012; 13(7): 696-706
30. Lim S-T, Fayad L, Tulpule A, et al A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkins lymphoma.Leuk Lymphoma 2007; 48(2): 374-80
31. Borchmann P, Herbrecht R, Wilhelm M, et al.Phase I/II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin lymphoma.Leuk Lymphoma 2011; 52(4): 620-8
32. Herbrecht R, Cernohous P, Engert A, et al.Comparison of pixantrone-based regimen (CPOP-R) with doxorubicinbased therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma.Ann Oncol 2013; 24(10): 2618-23
33. ClinicalTrials.gov.ClinicalTrials.gov [Internet] Available from: http://www.clinicaltrial.gov/.[Cited 24 January 2014
34. Srokowski TP, Liebmann JE, Modiano MR, et al.Pixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study with a dose-expansion cohort.Cancer 2011; 117(22): 5067-73
35. Faivre S, Raymond E, Boige V, et al A phase I and pharmacokinetic study of the novel aza-Anthracenedione compound BBR 2778 in patients with advanced solid malignancies.Clin Cancer Res 2001; 7(1): 43-50
36. Rigacci L, Puccini B, Cortelazzo S, et al.Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkins lymphoma patients: A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL). Ann hematol 2012; 91(7): 1013-22
37. Bose P, Batalo MS, Holkova B, Grant S.Bortezomib for the treatment of non-Hodgkins lymphoma.Expert Opin Pharmacother 2014; 15(16): 2443-59
38. Macpherson N, Belch A, Taylor M, et al.Liposomal encapsulated doxorubicin (Caelyx) in the treatment of relapsed aggressive non-Hodgkins lymphoma: a phase II study.Leuk Lymphoma 2006; 47(7): 1327-32
39. Tsavaris N, Kosmas C, Vadiaka M, et al.Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III/IV) non-Hodgkins lymphoma.Anticancer Res 2002; 22(3): 1845-8
40. Borchmann P, Schnell R, Knippertz R, et al.Phase I study of BBR 2778, a new aza-Anthracenedione, in advanced or refractory non-Hodgkins lymphoma.Ann Oncol 2001; 12(5): 661-7
41. Dawson LK, Jodrell DI, Bowman A, et al A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly.Eur J Cancer 2000; 36(18): 2353-9